Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding Zepbound and Mounjaro. Compounding of tirzepatide, ...
Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...
Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...
In a statement on its website, Eli Lilly and Company (LLY) said it has no affiliation with hims & hers (HIMS). It added, “Zepbound can be ...
Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.
The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...
Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass ...
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
BofA keeps an Underperform rating on Hims & Hers with a $22 price target after the company indicated it is adding a branded version of Eli ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback